{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:51:45Z","timestamp":1768999905777,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The authors studied the efficacy of neoadjuvant chemotherapy, consisting of a taxane, cisplatin, and 5\u2010fluorouracil (5\u2010FU) (the TPF regimen) followed by concurrent chemoradiation, in 2 separately designed and synchronously executed phase 2 trials for stage III and IVA\/IVB nasopharyngeal cancer (NPC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with newly diagnosed NPC were accrued to 2 trials, 1 for patients with stage III disease and the other for patients with IVA\/IVB disease. All patients received TPF (docetaxel 75 mg\/m<jats:sup>2<\/jats:sup>, cisplatin 75 mg\/m<jats:sup>2<\/jats:sup>, and 5\u2010FU 2500 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks for 3 cycles) followed by cisplatin 40 mg\/m<jats:sup>2<\/jats:sup> per week concurrently with either 3\u2010dimentional conformal radiation therapy or intensity\u2010modulated radiation therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>From January 2007 to July 2011, 52 eligible patients with stage III NPC and 64 eligible patients with nonmetastatic stage IV NPC were accrued. With a median follow\u2010up of 32.9 months, the 3\u2010year overall survival rates were 94.8% (95% confidence interval [CI], 87.6%\u2010100%) and 90.2% (95% CI, 81.8%\u201098.6%) for the stage III NPC group and the IVA\/IVB NPC group, respectively. The 3\u2010year progression\u2010free survival, distant metastasis\u2010free survival, and local progression\u2010free survival rates were 78.2% (95% CI, 64.6%\u201091.8%), 90.5% (95% CI, 79.7%\u2010100%), and 93.9%(87.1%\u2010100%), respectively, for patients with stage III NPC and 85.1% (95% CI, 75.1%\u201095.1%), 88% (95% CI, 78.6%\u201097.4%), and 100%, respectively, for patients with stage IVA\/IVB NPC. The most common severe (grade 3\/4) hematologic and nonhematologic adverse events were neutropenia (64 patients; 55.2%) and nausea\/vomiting (23 patients; 19.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Neoadjuvant TPF followed by concurrent chemoradiation was well tolerated and produced encouraging outcomes in patients with locally advanced NPC in this hypothesis\u2010generating study. The authors concluded that randomized controlled trials are warranted to definitively confirm this aggressive and potentially efficacious strategy. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013<\/jats:bold>;119:4111\u20134118. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28324","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T13:50:49Z","timestamp":1377611449000},"page":"4111-4118","source":"Crossref","is-referenced-by-count":49,"title":["Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"119","author":[{"given":"Lin","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Fudan University, Shanghai Cancer Center Shanghai People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Fudan University, Shanghai Cancer Center Shanghai People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshuang","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Fudan University, Shanghai Cancer Center Shanghai People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youwang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Fudan University, Shanghai Cancer Center Shanghai People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University, Shanghai Cancer Center Shanghai People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan W. K.","family":"Tham","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National University Cancer Institute National University of Singapore, National University Health System  Republic of Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiade Jay","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National University Cancer Institute National University of Singapore, National University Health System  Republic of Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.158"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji084"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.3863"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.16.790"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.7542"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1990"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-012-0020-4"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70320-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02781-X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1401"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.074"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.3.CO;2-K"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1350"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.081"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-012-0032-0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00558-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-005-1355-1"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1545"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.04.010"},{"key":"e_1_2_7_26_1","unstructured":"National Institutes of Health.Induction chemotherapy and chemoradiotherapy in nasopharyngeal cancers (GORTEC\u2010NPC2006). National Clinical Trial (NCT) 00828386. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00828386?term=GORTEC&rank=3. Accessed August 13 2013."},{"key":"e_1_2_7_27_1","unstructured":"National Institutes of Health.Induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: National Clinical Trial (NCT) 01245959. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01245959?term=nasopharyngeal+carcinoma&rank=13. Accessed August 13 2013."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-39"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28324","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:27:14Z","timestamp":1760264834000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28324"}},"subtitle":["Interim results from 2 prospective phase 2 clinical trials"],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/cncr.28324"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28324","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]}}}